Next Article in Journal
Effects of a Formula Containing Two Types of Prebiotics, Bifidogenic Growth Stimulator and Galacto-oligosaccharide, and Fermented Milk Products on Intestinal Microbiota and Antibody Response to Influenza Vaccine in Elderly Patients: A Randomized Controlled Trial
Next Article in Special Issue
Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Previous Article in Journal
A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2015, 8(2), 337-350;

Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism

Department of Internal Medicine, Biocenter, Innsbruck Medical University, Innsbruck 6020, Austria
Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck 6020, Austria
Department of Medicine III, Medical University of Vienna, Vienna 1090, Austria
Author to whom correspondence should be addressed.
Academic Editor: Howard A. Young
Received: 6 March 2015 / Revised: 11 May 2015 / Accepted: 12 May 2015 / Published: 18 June 2015
(This article belongs to the Special Issue Interferons 2015)
Full-Text   |   PDF [299 KB, uploaded 18 June 2015]   |  


Until recently, the standard treatment of chronic hepatitis C virus (HCV) infection was a combination therapy with PEG-IFN-α plus ribavirin. Previous studies have proven that several markers predict the outcome of such therapy, e.g., pretreatment plasma levels of interferon inducible protein IP-10, HCV RNA and IL28B-related single nucleotide polymorphisms (SNP). Altered activity of tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase (IDO) has been also shown in patients suffering from HCV infection. In this study, we investigated whether IL28B SNP in patients infected with HCV is related to the tryptophan breakdown rate. Before therapy, serum tryptophan and kynurenine concentrations were determined in 25 patients with established HCV infection and the kynurenine to tryptophan ratio (KYN/TRP) was calculated as an estimate of the tryptophan breakdown rate. In parallel, neopterin and nitrite concentrations were determined. A significant difference of serum KYN/TRP existed between the three IL28B polymorphism groups: C/C genotype had the highest and T/T genotype had the lowest KYN/TRP (p < 0.05). Likewise, C/C genotype was associated with higher KYN/TRP than non-C/C genotype (p = 0.01). There was a smaller difference between the three groups regarding the absolute kynurenine concentrations, the C/C genotype being associated with higher kynurenine concentrations. None of the other comparisons revealed any statistical significance. In conclusion, patients with C/C genotype presented with the highest tryptophan breakdown rate already before antiretroviral therapy with IFN-α/ribavirin. The differences in tryptophan metabolism might relate to HCV clearance and also to side effects of IFN-α therapy. View Full-Text
Keywords: IL28B polymorphism; tryptophan breakdown; indoleamine 2,3-dioxygenase; kynurenine to tryptophan ratio; neopterin IL28B polymorphism; tryptophan breakdown; indoleamine 2,3-dioxygenase; kynurenine to tryptophan ratio; neopterin

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zoller, H.; Jenal, A.; Staettermayer, A.F.; Schroecksnadel, S.; Ferenci, P.; Fuchs, D. Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. Pharmaceuticals 2015, 8, 337-350.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top